# Juan P. Frías

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/juan-p-frias/

## Facts

| Field | Value |
| --- | --- |
| Citations | 22,446 |
| Field | Diabetes Treatment and Management |
| h-index | 62 |
| i10-index | 128 |
| OpenAlex ID | https://openalex.org/A5086072427 |
| ORCID iD | https://orcid.org/0000-0001-9486-1255 |
| Works | 312 |

## Researcher papers

- [Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes](https://scholariq.org/papers/tirzepatide-versus-semaglutide-once-weekly-in-patients-with-type-2-diabetes/)
- [Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity](https://scholariq.org/papers/effect-of-subcutaneous-semaglutide-vs-placebo-as-an-adjunct-to-intensive/)
- [Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial](https://scholariq.org/papers/triple-hormone-receptor-agonist-retatrutide-for-obesity-a-phase-2-trial/)
- [Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial](https://scholariq.org/papers/two-year-effects-of-semaglutide-in-adults-with-overweight-or-obesity-the-step-5/)
- [Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial](https://scholariq.org/papers/efficacy-and-safety-of-ly3298176-a-novel-dual-gip-and-glp-1-receptor-agonist-in/)
- [Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial](https://scholariq.org/papers/tirzepatide-versus-insulin-glargine-in-type-2-diabetes-and-increased/)
- [Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial](https://scholariq.org/papers/once-weekly-tirzepatide-versus-once-daily-insulin-degludec-as-add-on-to/)
- [PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes](https://scholariq.org/papers/pioneer-1-randomized-clinical-trial-of-the-efficacy-and-safety-of-oral/)
- [Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial](https://scholariq.org/papers/exenatide-once-weekly-plus-dapagliflozin-once-daily-versus-exenatide-or/)
- [Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA](https://scholariq.org/papers/retatrutide-a-gip-glp-1-and-glucagon-receptor-agonist-for-people-with-type-2/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.